- Home
- IMMP
IMMP
Immutep Limited
as 03-31-2025 3:38pm EST
| Founded: | 1987 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 64.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.65 - $3.34 | Next Earning Date: | 04-08-2025 |
| Revenue: | $3,019,249 | Revenue Growth: | 24.11% |
| Revenue Growth (this year): | -32.74% | Revenue Growth (next year): | 20.28% |
Latest Immutep Limited News
IMMP Breaking Stock News: Dive into IMMP Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
GlobeNewswire
12 days ago
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025
Insider Monkey
22 days ago
Immutep Limited (IMMP): Among the Best Australian Stocks to Buy According to Billionaires
Insider Monkey
2 months ago
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?
GlobeNewswire
2 months ago
Immutep Quarterly Activities Report Q2 FY25
Insider Monkey
2 months ago
Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?
Insider Monkey
2 months ago
Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?
GlobeNewswire
2 months ago
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
Compare IMMP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMP Immutep Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.